Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−11.1 EUR
−450.04 M EUR
174.00 M EUR
20.55 M
About Madrigal Pharmaceuticals, Inc.
Sector
Industry
CEO
William J. Sibold
Website
Headquarters
West Conshohocken
Founded
2000
ISIN
US5588681057
FIGI
BBG01TNXBVD2
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
The current price of 1MDGL is 417.6 EUR — it has decreased by −2.18% in the past 24 hours. Watch Madrigal Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Madrigal Pharmaceuticals, Inc. stocks are traded under the ticker 1MDGL.
1MDGL stock has risen by 1.51% compared to the previous week, the month change is a 10.71% rise, over the last year Madrigal Pharmaceuticals, Inc. has showed a 51.41% increase.
We've gathered analysts' opinions on Madrigal Pharmaceuticals, Inc. future price: according to them, 1MDGL price has a max estimate of 522.13 EUR and a min estimate of 341.12 EUR. Watch 1MDGL chart and read a more detailed Madrigal Pharmaceuticals, Inc. stock forecast: see what analysts think of Madrigal Pharmaceuticals, Inc. and suggest that you do with its stocks.
1MDGL reached its all-time high on Oct 31, 2025 with the price of 411.4 EUR, and its all-time low was 237.5 EUR and was reached on May 29, 2025. View more price dynamics on 1MDGL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1MDGL stock is 2.23% volatile and has beta coefficient of 0.73. Track Madrigal Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Madrigal Pharmaceuticals, Inc. there?
Today Madrigal Pharmaceuticals, Inc. has the market capitalization of 9.62 B, it has decreased by −0.46% over the last week.
Yes, you can track Madrigal Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Madrigal Pharmaceuticals, Inc. is going to release the next earnings report on Mar 4, 2026. Keep track of upcoming events with our Earnings Calendar.
1MDGL earnings for the last quarter are −4.33 EUR per share, whereas the estimation was −1.95 EUR resulting in a −122.31% surprise. The estimated earnings for the next quarter are −0.83 EUR per share. See more details about Madrigal Pharmaceuticals, Inc. earnings.
Madrigal Pharmaceuticals, Inc. revenue for the last quarter amounts to 244.81 M EUR, despite the estimated figure of 210.78 M EUR. In the next quarter, revenue is expected to reach 270.08 M EUR.
1MDGL net income for the last quarter is −97.31 M EUR, while the quarter before that showed −35.89 M EUR of net income which accounts for −171.12% change. Track more Madrigal Pharmaceuticals, Inc. financial stats to get the full picture.
No, 1MDGL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2025, the company has 528 employees. See our rating of the largest employees — is Madrigal Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Madrigal Pharmaceuticals, Inc. EBITDA is −260.78 M EUR, and current EBITDA margin is −275.78%. See more stats in Madrigal Pharmaceuticals, Inc. financial statements.
Like other stocks, 1MDGL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Madrigal Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.